Suppr超能文献

抗生素联合用药是否应用于治疗呼吸机相关性肺炎?

Should antibiotic combinations be used to treat ventilator-associated pneumonia?

作者信息

Eggimann Philippe, Revelly Jean-Pierre

机构信息

Surgical Intensive Care and Burn Unit, Department of Surgery and Anesthesiology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.

出版信息

Semin Respir Crit Care Med. 2006 Feb;27(1):68-81. doi: 10.1055/s-2006-933675.

Abstract

This review summarizes the rationale for using or not using combinations of antibiotics to treat ventilator-associated pneumonia (VAP). Patients suffering from VAP require empirical antibiotic treatment before the identification of an etiologic agent. Most treatment failures are related to inappropriate initial antibiotic treatment with insufficient coverage of multidrug-resistant (MDR) pathogens. Guidelines require initial (empirical) treatment of VAP with a combination of antibiotics. However, this contributes to overexposure to antibiotics and further emergence of MDR microorganisms. We review the rationale for using combinations of antibiotics to cover MDR gram-negatives. However, clinical data supporting this strategy are limited. In fact, systematic combination therapy may have contributed to the overuse of antibiotics and to the emergence of MDR microorganisms. Nevertheless, combination therapy is our best strategy to treat severe infections due to suspected MDR microorganisms. Optimally, therapeutic strategies should be sufficiently broad to cover relevant pathogens while minimizing the risk for emergence of antimicrobial resistance.

摘要

本综述总结了使用或不使用抗生素联合治疗呼吸机相关性肺炎(VAP)的理论依据。患有VAP的患者在确定病原体之前需要进行经验性抗生素治疗。大多数治疗失败与初始抗生素治疗不当、对多重耐药(MDR)病原体覆盖不足有关。指南要求对VAP进行初始(经验性)抗生素联合治疗。然而,这会导致抗生素过度暴露以及MDR微生物的进一步出现。我们回顾了使用抗生素联合治疗MDR革兰阴性菌的理论依据。然而,支持该策略的临床数据有限。事实上,系统性联合治疗可能导致了抗生素的过度使用以及MDR微生物的出现。尽管如此,联合治疗仍是我们治疗疑似MDR微生物所致严重感染的最佳策略。理想情况下,治疗策略应足够广泛以覆盖相关病原体,同时将出现抗菌药物耐药性的风险降至最低。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验